Rolf Einar Engstad

Direttore/Membro del Consiglio presso Biotec BetaGlucans AS

65 anni

Health Technology

Consumer Services

Posizioni attive di Rolf Einar Engstad

Società	Posizione	Inizio	Fine
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Direttore/Membro del Consiglio	-	-

Società	Posizione	Inizio	Fine
ARCTICZYMES TECHNOLOGIES ASA	Direttore Tecnico/Scientifico/R&S	01/01/1999	-

University of Tromso

Doctorate Degree

Distribuzione geografica

Norvegia

Posizioni

Settori

Health Technology	3
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Società quotate in Borsa	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Aziende private	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology

Aziende private

Health Technology